Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2025)

Historic Current Assets for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $312.4 million.

  • 4D Molecular Therapeutics' Current Assets fell 3884.04% to $312.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.4 million, marking a year-over-year decrease of 3884.04%. This contributed to the annual value of $434.9 million for FY2024, which is 4664.52% up from last year.
  • 4D Molecular Therapeutics' Current Assets amounted to $312.4 million in Q3 2025, which was down 3884.04% from $303.3 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Current Assets high stood at $552.6 million for Q2 2024, and its period low was $165.7 million during Q3 2021.
  • Its 5-year average for Current Assets is $316.3 million, with a median of $296.6 million in 2023.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Current Assets surged by 15868.87% in 2024 and then tumbled by 4511.96% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Current Assets (Quarter) stood at $256.3 million in 2021, then dropped by 13.96% to $220.5 million in 2022, then skyrocketed by 34.5% to $296.6 million in 2023, then soared by 46.65% to $434.9 million in 2024, then decreased by 28.18% to $312.4 million in 2025.
  • Its last three reported values are $312.4 million in Q3 2025, $303.3 million for Q2 2025, and $332.6 million during Q1 2025.